Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 17 Prostatic Neoplasms 6 Ovarian Neoplasms 6 Neoplasms 5 Triple Negative Breast Neoplasms 4 Neoplasm Metastasis 4 Stomach Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Solid Tumors 2 Multiple Myeloma 2 Mouth Neoplasms 2 Lymphoma 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Cancers 1 Skin Diseases 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1

Interventions

Carboplatin 12 Paclitaxel 11 Gemcitabine 11 Capecitabine 7 Irinotecan 6 Fluorouracil 5 Cisplatin 5 Radiotherapy 4 Oxaliplatin 4 Leucovorin 4 Bevacizumab 4 pembrolizumab 3 Filgrastim 3 Etoposide 3 Erlotinib Hydrochloride 3 Cyclophosphamide 3 etoposide phosphate 2 atezolizumab 2 Trastuzumab 2 Topotecan 2 Taxes 2 Surveys and Questionnaires 2 Peripheral Blood Stem Cell Transplantation 2 Magnetic Resonance Spectroscopy 2 Genetic Testing 2 FAPI-46 2 Docetaxel 2 CP protocol 2 Amifostine 2 Albumin-Bound Paclitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Unknown Primary × ipatasertib × Clear all

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡